ID27833A - METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA - Google Patents

METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA

Info

Publication number
ID27833A
ID27833A IDW20010626A ID20010626A ID27833A ID 27833 A ID27833 A ID 27833A ID W20010626 A IDW20010626 A ID W20010626A ID 20010626 A ID20010626 A ID 20010626A ID 27833 A ID27833 A ID 27833A
Authority
ID
Indonesia
Prior art keywords
aterosclelerosis
inhibitors
combinations
treatment
methods
Prior art date
Application number
IDW20010626A
Other languages
English (en)
Indonesian (id)
Inventor
Jeffry A Robl
Rex A Parker
Scott A Biller
Haris Jamil
Bruce L Jacobson
Krishna Kudukula
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID27833(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ID27833A publication Critical patent/ID27833A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
IDW20010626A 1998-09-17 1999-09-13 METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA ID27833A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10067798P 1998-09-17 1998-09-17

Publications (1)

Publication Number Publication Date
ID27833A true ID27833A (id) 2001-04-26

Family

ID=22280975

Family Applications (2)

Application Number Title Priority Date Filing Date
IDW20010626A ID27833A (id) 1998-09-17 1999-09-13 METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA
IDW20010624A ID28450A (id) 1998-09-17 1999-09-13 METODA UNTUK MENGOBATI DIABETES DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA

Family Applications After (1)

Application Number Title Priority Date Filing Date
IDW20010624A ID28450A (id) 1998-09-17 1999-09-13 METODA UNTUK MENGOBATI DIABETES DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA

Country Status (30)

Country Link
US (1) US20020035064A1 (lt)
EP (2) EP1113801A4 (lt)
JP (2) JP2002524517A (lt)
KR (2) KR20010079842A (lt)
CN (2) CN1319012A (lt)
AT (1) ATE406898T1 (lt)
AU (2) AU754488B2 (lt)
BG (2) BG105432A (lt)
BR (2) BR9913833A (lt)
CA (2) CA2344309A1 (lt)
CO (2) CO5130026A1 (lt)
CZ (2) CZ2001964A3 (lt)
DE (1) DE69939481D1 (lt)
EE (2) EE04356B1 (lt)
ES (1) ES2311306T3 (lt)
GE (2) GEP20033044B (lt)
HU (2) HUP0104240A2 (lt)
ID (2) ID27833A (lt)
IL (2) IL141786A0 (lt)
LT (2) LT4870B (lt)
LV (2) LV12687B (lt)
NO (2) NO20011352L (lt)
NZ (2) NZ510209A (lt)
PE (2) PE20001056A1 (lt)
PL (2) PL346660A1 (lt)
SK (1) SK3202001A3 (lt)
TR (2) TR200100773T2 (lt)
UY (2) UY25714A1 (lt)
WO (2) WO2000015230A1 (lt)
ZA (2) ZA200207430B (lt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1172999A (en) * 1997-11-19 1999-06-07 Takeda Chemical Industries Ltd. Novel apoptosis inhibitors
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
DE60041246D1 (de) * 1999-02-12 2009-02-12 Harvard College Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
WO2001054694A1 (en) 2000-01-28 2001-08-02 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
WO2002040448A1 (en) * 2000-11-20 2002-05-23 Bristol-Myers Squibb Company Pyridone derivatives as ap2 inhibitors
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
EP1414461A4 (en) 2001-07-13 2005-10-26 Bristol Myers Squibb Co PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD
WO2003007888A2 (en) * 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
CA2513102C (en) 2003-01-27 2011-03-22 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
EP1620089A4 (en) * 2003-03-26 2008-12-24 Crc For Asthma Ltd Therapeutic and prophylactic compositions and their uses
WO2004096977A2 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
SI1725234T1 (sl) 2004-03-05 2013-04-30 The Trustees Of The University Of Pennsylvania Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
SI1756064T1 (sl) 2004-06-04 2008-12-31 Merck & Co Inc Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
EP1919882A2 (en) 2005-02-17 2008-05-14 Synta Pharmaceuticals Corporation Isoxazole combretastatin derivatives for the treatment of proliferative disorders
US7709658B2 (en) 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
US20070088089A1 (en) * 2005-10-18 2007-04-19 Wisler Gerald L Methods for treating disorders associated with hyperlipidemia in a mammal
WO2007143164A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
EP2120927A1 (en) * 2006-12-21 2009-11-25 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
WO2010056631A1 (en) * 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
PT2403605E (pt) 2009-03-05 2015-08-05 Harvard College Composições contendo um anticorpo específico de ap2 ou um seu fragmento, para serem utilizadas no tratamento de diabetes, intolerância à glicose ou resistência à insulina induzida por obesidade
JP6223376B2 (ja) 2014-03-24 2017-11-01 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6514282B2 (ja) * 2014-03-24 2019-05-15 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
KR20170138570A (ko) 2015-04-30 2017-12-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
BR112018076703A2 (pt) * 2016-06-27 2019-04-02 President And Fellows Of Harvard College compostos úteis para tratar distúrbios metabólicos
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
WO2021263246A1 (en) 2020-06-27 2021-12-30 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof
EP4188372A1 (en) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2129012A1 (de) 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
FR2156486A1 (en) 1971-10-22 1973-06-01 Roussel Uclaf Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (lt) 1974-06-07 1981-03-18
GB1507032A (en) 1974-08-06 1978-04-12 Serono Lab 2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
AU610591B2 (en) 1987-05-22 1991-05-23 E.R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
PT95690A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr) 1990-06-14 1994-05-06 Bellon Laboratoires Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
US5254576A (en) * 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de) 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
JPH09506894A (ja) * 1993-12-20 1997-07-08 藤沢薬品工業株式会社 ４，５−ジアリールオキサゾール誘導体
US5599770A (en) 1994-07-15 1997-02-04 Kureha Kagaku Kogyo Kabushiki Kaisha Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk) 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en) 1996-01-05 1996-03-06 Foster Wheeler Petrol Dev Ltd Spacing bouy for flexible risers
AUPO134596A0 (en) 1996-08-01 1996-08-22 Jal Pastoral Co. Pty Ltd Demountable article carrier for motor vehicles
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
CA2344309A1 (en) 2000-03-23
HUP0104108A2 (hu) 2002-03-28
EP1121129B1 (en) 2008-09-03
TR200100773T2 (tr) 2001-07-23
LT4870B (lt) 2001-12-27
JP2002524517A (ja) 2002-08-06
GEP20033044B (en) 2003-08-25
LT2001023A (lt) 2001-08-27
AU754488B2 (en) 2002-11-14
BR9913831A (pt) 2001-05-29
AU6143799A (en) 2000-04-03
LT4871B (lt) 2001-12-27
LV12686B (lv) 2001-10-20
NZ510207A (en) 2003-08-29
GEP20033045B (en) 2003-08-25
KR20010079842A (ko) 2001-08-22
CZ2001964A3 (cs) 2002-01-16
WO2000015229A1 (en) 2000-03-23
ATE406898T1 (de) 2008-09-15
EE04356B1 (et) 2004-10-15
US20020035064A1 (en) 2002-03-21
CN1317970A (zh) 2001-10-17
NO20011351L (no) 2001-05-11
EE200100154A (et) 2002-12-16
NZ510209A (en) 2003-07-25
ZA200207433B (en) 2003-10-27
CO5130025A1 (es) 2002-02-27
EP1113801A1 (en) 2001-07-11
UY25714A1 (es) 2001-08-27
BG105432A (en) 2001-12-29
EP1113801A4 (en) 2002-10-02
NO20011351D0 (no) 2001-03-16
NO20011352L (no) 2001-05-11
PL346660A1 (en) 2002-02-25
LV12687B (lv) 2001-10-20
PE20001047A1 (es) 2000-12-24
HUP0104240A2 (hu) 2002-03-28
SK3202001A3 (en) 2002-04-04
NO20011352D0 (no) 2001-03-16
EP1121129A1 (en) 2001-08-08
ID28450A (id) 2001-05-24
LT2001022A (lt) 2001-08-27
BG105431A (en) 2001-12-29
JP2002524518A (ja) 2002-08-06
AU755563B2 (en) 2002-12-12
AU6387799A (en) 2000-04-03
CA2344300A1 (en) 2000-03-23
CO5130026A1 (es) 2002-02-27
UY25713A1 (es) 2001-08-27
EE200100155A (et) 2002-08-15
WO2000015230A1 (en) 2000-03-23
LV12687A (en) 2001-07-20
IL141786A0 (en) 2002-03-10
EP1121129A4 (en) 2002-10-16
KR20010075150A (ko) 2001-08-09
ES2311306T3 (es) 2009-02-01
PE20001056A1 (es) 2000-12-24
TR200100774T2 (tr) 2001-12-21
DE69939481D1 (de) 2008-10-16
ZA200207430B (en) 2003-09-16
LV12686A (en) 2001-07-20
PL346661A1 (en) 2002-02-25
CZ2001965A3 (cs) 2002-02-13
IL141785A0 (en) 2002-03-10
CN1319012A (zh) 2001-10-24
BR9913833A (pt) 2001-05-29

Similar Documents

Publication Publication Date Title
ID27833A (id) METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
BR9714364A (pt) Amidas inibidoras da secreção de apo b/mtp
BG101717A (bg) Инхибитори на микрозомалния триглицерид пренасящ белтък и метод
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
BR9811099A (pt) Inibidores de urocinase
ES2167733T3 (es) Inhibidores de metaloproteinasa matricial de bifenilsulfonamida.
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
FI944926L (fi) Entsymaattinen hydroksylaatiomenetelmä HMG-CoA-reduktaasi-inhibiittorien ja niiden välituotteiden valmistamiseksi
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
EP1466623A4 (en) CURE AGAINST ARTHRITIS
MY140504A (en) Statin-mmp inhibitor combinations
BR0112460A (pt) Método para tratamento de sépsis
EP1009421A4 (en) METHODS AND COMPOSITIONS FOR IMPROVING HEALING INJURIES
ATE234800T1 (de) Verfahren zur synthese von taxanen
BR9807920A (pt) Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência
IT1255470B (it) Composti attivi come inibitori dell&#39;enzima hmg-coa reduttasi
ECSP992885A (es) Combinaciones de estatina-inhibidor de mmp
ECSP961804A (es) Nuevos compuestos monociclicos de b -.lactama